The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

US biotech PTC Therapeutics released mixed new data on its Phase II trial of PCT187 (votoplam) in Huntington’s disease. UK ...

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s ...